Lazard Asset Management LLC Seagen Inc. Transaction History

Lazard Asset Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $10,724 - $12,104	56 Added 430.77%	69 $14,000
Q2 2023 Aug 14, 2023	SELL	$187.64 - $206.25 $14,823 - $16,293	-79 Reduced 85.87%	13 $2,000
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $9,441 - $15,027	74 Added 411.11%	92 $18,000
Q4 2022 Feb 14, 2023	SELL	$117.37 - $139.17 $94,248 - $111,753	-803 Reduced 97.81%	18 $2,000
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $54,378 - $72,404	402 Added 95.94%	821 $112,000

Q2 2022 Aug 09, 2022	BUY	$108.81 - $179.33 $15,777 - $26,002	145 Added 52.92%	419 $73,000
Q1 2022 May 13, 2022	SELL	$119.61 - $157.85 $577,118 - $761,626	-4,825 Reduced 94.63%	274 $39,000
Q4 2021 Feb 09, 2022	SELL	$142.57 - $190.86 $100,654 - $134,747	-706 Reduced 12.16%	5,099 $787,000
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $417,948 - $498,251	2,934 Added 102.19%	5,805 $985,000
Q2 2021 Aug 12, 2021	SELL	$135.08 - $161.1 $77,806 - $92,793	-576 Reduced 16.71%	2,871 $452,000
Q1 2021 May 14, 2021	SELL	$137.51 - $190.8 $18.3 Million - $25.3 Million	-132,814 Reduced 97.47%	3,447 $478,000
Q4 2020 Feb 11, 2021	BUY	$164.63 - $211.93 $22.4 Million - $28.9 Million	136,261 New	136,261 $23.9 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.